A trial of fexagratinib with cisplatin and capecitabine for advanced cancer (FACING)
Cancer type:
Status:
Phase:
This trial looked at fexagratinib and chemotherapy for people with cancer that had come back after treatment.
The trial was supported by Cancer Research UK. It was open for people to join between 2012 and 2015. The research team analysed the results in 2019. There is a link to more information in the ‘Summary of results’ section below.
More about this trial
Fexagratinib (AZD4547) is a type of targeted cancer treatment called a cancer growth blocker. It helps stop the signals that cancer cells need to divide and grow.
It stops signals from a specific 
called fibroblast growth factor (FGF). A called FCFR2 controls the amount of FGF that cells produce. Researchers hoped fexagratinib would work for people whose cancer cells have more copies of the FGFR2 gene.
There were 2 parts to this trial.
The first part was for people with different types of cancer. People in this part had different doses of fexagratinib. This was so the research team could find the best dose to give.
The second part was for people with advanced cancer of the stomach or oesophagus. People in this part were put into a treatment group at random:
- half had cisplatin, capecitabine and fexagratinib
- half had cisplatin, capecitabine and a dummy drug (placebo)
The main aims of the trial were to find out:
- the best dose of fexagratinib to give
- if fexagratinib and chemotherapy helps people with advanced cancer and more copies of the FGFR2 gene
Summary of results
We aim to add a lay summary of results to all the trials on our database. Unfortunately we have not been able to include a summary for this one.
There is more information about the results in the link below.
Please note, the information we link to here is not in plain English. It has been written for healthcare professionals and researchers.
A Phase I/IIa trial of AZD4547 in combination with Cisplatin and Capecitabine (CX)
EU Clinical Trials Register
Accessed April 2024
Recruitment start:
Recruitment end:
How to join a clinical trial
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Chief Investigator
Professor Jeff Evans
Supported by
AstraZeneca
Cancer Research UK
Experimental Cancer Medicine Centre (ECMC)
NHS Greater Glasgow and Clyde
NIHR Clinical Research Network: Cancer
University of Glasgow
Other information
This is Cancer Research UK trial number CRUKD/11/003.
If you have questions about the trial please contact our cancer information nurses
Freephone 0808 800 4040
